Vessel Size Index Magnetic Resonance Imaging to Monitor the Effect of Antivascular Treatment in a Rodent Tumor Model

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1470-1476

  Howe, Franklyn A ^a   McPhail, Lesley D ^b   Griffiths, John R ^c   McIntyre, Dominick J O ^c   Robinson, Simon P ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Antivascular; Blood flow; Blood volume; Magnetic resonance imaging; MRI; Tumor

Indexed keywords

ACETIC ACID; AGENTS; ATOMS; BIOMARKERS; BLOOD; BLOOD VESSELS; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; HEMODYNAMICS; IMAGING TECHNIQUES; IRON; IRON OXIDES; MAGNETIC FIELDS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MAGNETISM; NORMAL DISTRIBUTION; ONCOLOGY; PARAMAGNETISM; RESONANCE; SUPERPARAMAGNETISM;

AFTER-TREATMENT; ANTI-CANCER AGENTS; ANTIVASCULAR; BIOMARKER; BLOOD FLOW; BLOOD VOLUME; CONTRAST AGENT; HISTOGRAM ANALYSIS; INTRAVASCULAR; MRI; SENSITIVE INDICATOR; TUMOR; TUMOR MODELS; TUMOR NECROSIS; TUMOR RESPONSE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULAR COLLAPSE; VESSEL SIZE;

TUMORS;

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD VESSEL; BLOOD VOLUME; CONTROLLED STUDY; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; BLOOD VOLUME; BLOOD VOLUME DETERMINATION; CONTRAST MEDIA; FEMALE; IRON; MAGNETIC RESONANCE IMAGING; ORGAN SIZE; OXIDES; PROLACTINOMA; RATS; RATS, INBRED WF; REGIONAL BLOOD FLOW; XANTHONES;

EID: 47149108868     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.027     Document Type: Article

References (26)

1. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
2. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
3. Chaplin D.J., Pettit G.R., and Hill S.A. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19 (1999) 189-195
4. Siemann D.W., and Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60 (2004) 1233-1240
5. Leach M.O., Brindle K.M., Evelhoch J.L., et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: Recommendations for appropriate methodology for clinical trials. Br J Radiol 76 (2003) S87-S91
6. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
7. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
8. Siemann D.W., Bibby M.C., Dark G.G., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420
9. Zhao L., Ching L.M., Kestell P., et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116 (2005) 322-326
10. Ching L.M., Zwain S., and Baguley B.C. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90 (2004) 906-910
11. Galbraith S.M., Rustin G.J., Lodge M.A., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
12. McKeage M.J., Fong P., Jeffery M., et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 12 (2006) 1776-1784
13. Beauregard D.A., Pedley R.B., Hill S.A., et al. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15 (2002) 99-105
14. McPhail L.D., McIntyre D.J., Ludwig C., et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (2006) 199-206
15. McPhail L.D., Chung Y.L., Madhu B., et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11 (2005) 3705-3713
16. Enochs W.S., Harsh G., Hochberg F., et al. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 9 (1999) 228-232
17. Dennie J., Mandeville J.B., Boxerman J.L., et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40 (1998) 793-799
18. Tropres I., Grimault S., Vaeth A., et al. Vessel size imaging. Magn Reson Med 45 (2001) 397-408
19. Robinson S.P., Kalber T.L., Howe F.A., et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7 (2005) 466-474
20. Bentzen L., Vestergaard-Poulsen P., Nielsen T., et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 61 (2005) 1208-1215
21. Robinson S.P., Howe F.A., Griffiths J.R., et al. Susceptibility contrast magnetic resonance imaging determination of fractional tumour blood volume: A non-invasive imaging biomarker of response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol Phys 69 (2007) 872-879
22. Ferretti S., Allegrini P.R., O'Reilly T., et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11 (2005) 7773-7784
23. Workman P., Twentyman P., Balkwill F., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
24. Jackson A., O'Connor J.P., Parker G.J., et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13 (2007) 3449-3459
25. McIntyre D.J., Robinson S.P., Howe F.A., et al. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia 6 (2004) 150-157
26. Ma J., and Wehrli F.W. Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. J Magn Reson B 111 (1996) 61-69